Journal
EUROPEAN NEUROLOGY
Volume 62, Issue 1, Pages 9-15Publisher
KARGER
DOI: 10.1159/000215876
Keywords
Ischemic stroke; Thrombolysis; Biomarker; Infarct volume
Categories
Funding
- Institute Born-Bunge
- University of Antwerp
- Belgian Federal Science Policy Office, Belgium [P6/43]
- Medical Research Foundation Antwerp
Ask authors/readers for more resources
Introduction: We investigated the predictive value of standard neurological evaluation, a commercially available biomarker assay and neuroimaging in the subacute phase for outcome after thrombolytic therapy in ischemic stroke. Methods: Thirty-four consecutive ischemic stroke patients were evaluated by means of the NIH Stroke Scale (NIHSS72), the Triage (R) Stroke Panel (MMX72) and standardized infarct volumetry at 72 h after treatment with intravenous recombinant tissue plasminogen activator or intra-arterial urokinase. Outcome was assessed by the modified Rankin Scale (mRS) at 3 months after the stroke. Results: NIHSS72, MMX72 and infarct volume correlated significantly with the mRS score at month 3 and emerged as independent outcome predictors from logistic regression analysis. NIHSS72 is the best predictor for outcome, but its accuracy increases by 9 and 6% when combined with MMX72 and infarct volumetry, respectively. The combined use of NIHSS72 and MMX72 allows long-term outcome prediction with 97% accuracy, which is not further improved by infarct volumetry. Conclusions: Routine clinical evaluation, bedside testing of biochemical markers by the Triage Stroke Panel and infarct volumetry on neuroimaging at 72 h after thrombolytic therapy are predictors for long-term outcome of ischemic stroke patients. Clinical assessment is the most reliable parameter for outcome prediction, but its predictive value is substantially improved when combined with the biomarker panel. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available